INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled clinical trial in which patients with
major depressive disorder will receive augmentation through minocycline (MCO), celecoxib
(CXB) or placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Universiteit Antwerpen
Collaborators:
Amsterdam UMC, location VUmc KU Leuven Research Foundation Flanders Vrije Universiteit Brussel